NYSE: DNAGinkgo Bioworks Holdings Inc Stock
$6.53-0.39 (-5.64%)
Updated Aug 18, 2026
DNA Price
$6.53
Fair Value Price
N/A
Market Cap
$439.73M
52 Week Low
$5.37
52 Week High
$17.58
P/E
-1.3x
P/B
1.05x
P/S
5.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$111.86M
Earnings
-$290.80M
Gross Margin
77.7%
Operating Margin
-260.49%
Profit Margin
-260%
Debt to Equity
1.36
Operating Cash Flow
-$170M
Beta
2.56
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DNA Overview
Spinning Eagle Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Los Angeles, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DNA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DNA
Ranked#160 of 464
Ranked#160 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.24 | A | |
| $118.10 | A | |
| $6.75 | A |
Be the first to know about important DNA news, forecast changes, insider trades & much more!
DNA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DNA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DNA is good value based on its book value relative to its share price (1.05x), compared to the US Biotechnology industry average (5.4x)
P/B vs Industry Valuation
DNA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DNA due diligence checks available for Premium users.
Valuation
DNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.3x
Industry
18.39x
Market
15.03x
DNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.05x
Industry
5.4x
DNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DNA's financial health
Profit margin
Revenue
$20.2M
Net Income
-$46.7M
Profit Margin
-231.7%
DNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$990.0M
Liabilities
$569.8M
Debt to equity
1.36
DNA's short-term assets ($332.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DNA's long-term liabilities ($497.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$44.3M
Investing
$11.1M
Financing
$16.5M
DNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DNA vs Biotech Stocks
Ginkgo Bioworks Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.